AZ and Merck & Co ovarian cancer drug gets expanded US use
August 18, 2017FDA approves Lynparza’s use in a wider group of women.
X
AZ and Merck & Co ovarian cancer drug gets expanded US use
https://pharmaphorum.com/news/az-merck-lynparza/
ovarian cancer
Angle poised to take on US cancer diagnostics market
July 6, 2017Circulating tumour cell test could help select drug therapy.
AZ highlights data from next-gen oncology drugs at ASCO
May 26, 2017Tesara and Takeda among other companies to publish data.
Doubts over AbbVie PARP inhibitor after double trial failure
April 20, 2017Veliparib fails in two phase 3 trials.
Tesaro’s niraparib approved in ovarian cancer
March 28, 2017Company nabs maintenance therapy use, but problems on breast cancer trial.
AZ’s Lynparza impresses with new ovarian cancer data
March 15, 2017UK firm lays down the gauntlet in the PARP inhibitor battle.
AZ looks to file Lynparza in breast cancer
February 17, 2017UK pharma also gets $130m payment from Valeant.
Early Clovis approval notches up competition in ovarian cancer
December 20, 2016Clovis’ Rubraca will compete against AstraZeneca rival.
1 2
